Cargando…

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Mostrar otras versiones (1)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boucau, Julie, Chew, Kara W., Choudhary, Manish C., Deo, Rinki, Regan, James, Flynn, James P., Crain, Charles R., Hughes, Michael D., Ritz, Justin, Moser, Carlee, Dragavon, Joan A., Javan, Arzhang C., Nirula, Ajay, Klekotka, Paul, Greninger, Alexander L., Coombs, Robert W., Fischer, William A., Daar, Eric S., Wohl, David A., Eron, Joseph J., Currier, Judith S., Smith, Davey M., Li, Jonathan Z., Barczak, Amy K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213028/ https://www.ncbi.nlm.nih.gov/pubmed/35793677 http://dx.doi.org/10.1016/j.xcrm.2022.100678

Ejemplares similares

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
por: Boucau, Julie, et al.
Publicado: (2021)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2023)

Viral and Symptom Rebound in Untreated COVID-19 Infection
por: Deo, Rinki, et al.
Publicado: (2022)

878. Association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death for Non-Hospitalized Adults with Mild-to-Moderate COVID-19
por: Giganti, Mark, et al.
Publicado: (2022)

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial
por: Chew, Kara W., et al.
Publicado: (2021)

881. Nasal and Plasma SARS-CoV-2 RNA Levels Predict Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19
por: Li, Yijia, et al.
Publicado: (2022)

Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
por: Moser, Carlee B, et al.
Publicado: (2023)

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19
por: Moser, Carlee, et al.
Publicado: (2022)

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
por: Bender Ignacio, Rachel A., et al.
Publicado: (2023)

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
por: Ramirez, Sydney I., et al.
Publicado: (2022)

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
por: Jagannathan, Prasanna, et al.
Publicado: (2023)

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
por: Phan, Tin, et al.
Publicado: (2023)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay
por: Regan, James, et al.
Publicado: (2022)

Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19
por: Smith, Davey M., et al.
Publicado: (2022)

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance
por: Degli-Angeli, Emily, et al.
Publicado: (2020)

SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
por: Li, Yijia, et al.
Publicado: (2023)

1609 Plasma markers of immune activation likely reflect related but distinct processes of cellular immune activation in HIV-infected persons before and after suppression of viremia by antiretroviral therapy: ACTG 5260
por: Kelesidis, Theodoros, et al.
Publicado: (2014)

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates
por: Mollan, Katie R., et al.
Publicado: (2021)

Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections
por: Siedner, Mark J., et al.
Publicado: (2022)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Virologic features of SARS-CoV-2 infection in children
por: Yonker, Lael M., et al.
Publicado: (2021)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

Acute Infections, Cost per Infection and Turnaround Time in Three United States Hospital Laboratories Using Fourth-Generation Antigen-Antibody Human Immunodeficiency Virus Immunoassays
por: Wesolowski, Laura G., et al.
Publicado: (2015)

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
por: Donnell, Deborah, et al.
Publicado: (2017)

Compartmentalization of HIV-1 within the Female Genital Tract Is Due to Monotypic and Low-Diversity Variants Not Distinct Viral Populations
por: Bull, Marta, et al.
Publicado: (2009)

TLR2 is non-redundant in the population and subpopulation responses to Mycobacterium tuberculosis in macrophages and in vivo
por: Jani, Charul, et al.
Publicado: (2023)

Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect
por: Menezes, Prema, et al.
Publicado: (2011)

Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection
por: El Kamari, Vanessa, et al.
Publicado: (2021)

Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2019)

HIV-1 RNA May Decline More Slowly in Semen than in Blood following Initiation of Efavirenz-Based Antiretroviral Therapy
por: Graham, Susan M., et al.
Publicado: (2012)

Duration of viable virus shedding in SARS-CoV-2 omicron variant infection
por: Boucau, Julie, et al.
Publicado: (2022)

Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection
por: Boucau, Julie, et al.
Publicado: (2022)

Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination
por: North, Crystal M, et al.
Publicado: (2021)

Open abdomen critical care management principles: resuscitation, fluid balance, nutrition, and ventilator management
por: Chabot, Elizabeth, et al.
Publicado: (2017)

The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Chew, Kara W., et al.
Publicado: (2014)

At Mean 30-Year Follow-Up, Cervical Spine Disease Is Common and Associated with Thoracic Hypokyphosis after Pediatric Treatment of Adolescent Idiopathic Scoliosis
por: Young, Ernest, et al.
Publicado: (2022)

Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds
por: Wamhoff, Eike-Christian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8igvttll0jbme05o1gt75g0ehl